Skip to main content
. 2023 Feb 21;15(4):1367. doi: 10.3390/cancers15051367

Figure 3.

Figure 3

Independent stool-based data for recruited independent patients. (a) Comparison of levels of miR-92a from CRC patients and health controls; (b) ROC analysis using miR-92 to discriminate CRC; (ce) The detection rate of miR-92a compared across CRC lymph node metastasis, stage, and tumor size, respectively. **** p < 0.0001.